Results 121 to 130 of about 20,432 (139)

CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz

Clinical Infectious Diseases, 2021
Godspower Akpomiemie, Phumla Sinxadi, Simiso Sokhela   +2 more
exaly  

Comparison of First-Line Antiretroviral Therapy With Regimens Including Nevirapine, Efavirenz, or Both Drugs, Plus Stavudine and Lamivudine: A Randomised Open-Label Trial, the 2NN Study

Lancet, The, 2004
Frank van Leth, Ma Johnson, F Mulcahy
exaly  

Rilpivirine Versus Efavirenz With Tenofovir and Emtricitabine in Treatment-Naive Adults Infected With HIV-1 (ECHO): A Phase 3 Randomised Double-Blind Active-Controlled Trial

Lancet, The, 2011
Sharon Walmsley, Anthony M. Mills, Khuanchai Supparatpinyo   +2 more
exaly  

Efavirenz: A Review

Expert Opinion on Pharmacotherapy, 2007
Ferdinand Wnm Wit, Joep M A Lange, Joep Ma Lange   +2 more
exaly  

Neuronal Toxicity of Efavirenz: A Systematic Review

Expert Opinion on Drug Safety, 2013
Eric H Decloedt, Gary Maartens
exaly  

Safety and Efficacy of Raltegravir-Based Versus Efavirenz-Based Combination Therapy in Treatment-Naive Patients With HIV-1 Infection: A Multicentre, Double-Blind Randomised Controlled Trial

Lancet, The, 2009
Jeffrey L Lennox, Adriano Lazzarin, José Valdez Ramalho Madruga   +2 more
exaly  

High Prevalence of the CYP2B6 516G→T(*6) Variant and Effect on the Population Pharmacokinetics of Efavirenz in HIV/AIDS Outpatients in Zimbabwe

European Journal of Clinical Pharmacology, 2008
Collen Masimirembwa, Daniel Röshammar, Emmanuel Chigutsa   +2 more
exaly  

Consequences of a Chronic Exposure of Cultured Brain Astrocytes to the Anti-Retroviral Drug Efavirenz and Its Primary Metabolite 8-Hydroxy Efavirenz

Neurochemical Research, 2016
Stefan Stolte, Ralf Dringen, Christian Arend   +2 more
exaly  

Rilpivirine Versus Efavirenz With Two Background Nucleoside or Nucleotide Reverse Transcriptase Inhibitors in Treatment-Naive Adults Infected With HIV-1 (THRIVE): A Phase 3, Randomised, Non-Inferiority Trial

Lancet, The, 2011
Kiat Ruxrungtham, Carmen D Zorrilla, Jaime F Andrade-Villanueva   +2 more
exaly  

Cerebrospinal Fluid Exposure of Efavirenz and Its Major Metabolites When Dosed at 400 mg and 600 mg Once Daily: A Randomized Controlled Trial

Clinical Infectious Diseases, 2015
Sean Emery, Ploenchan Chetchotisak, Saye Khoo   +2 more
exaly